MAPS: Celebrating 33 Years

The Multidisciplinary Association for Psychedelic Studies (MAPS) marks 33 years of progress in psychedelic research and education since its founding by Rick Doblin in 1986. The organization developed from an initial focus on MDMA legalization into an expansive research program covering conditions like PTSD through FDA-regulated trials, achieving Breakthrough Therapy Designation from the FDA in 2017. Beyond research, the organization has cultivated a broad community through conferences on psychedelic science, the publication of the MAPS Bulletin, and the creation of specialized entities such as the Zendo Project and the MDMA Therapy Training Program. These efforts have established legal, medical, and cultural foundations for utilizing substances like LSD, ayahuasca, ibogaine, and cannabis for their therapeutic potential.